Common Adverse Events Associated With FGFRi Therapy

EP: 1.Intrahepatic Cholangiocarcinoma Overview

EP: 2.Risk Factors Leading to Various Liver Cancers

EP: 3.Clinical Presentations of Patients With Cholangiocarcinoma

EP: 4.The Role of Biomarker Testing in Diagnosing Cholangiocarcinoma

EP: 5.First- and Second-Line Treatment Options for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions or Alterations

EP: 6.Next-Gen Inhibitors Shaping Cholangiocarcinoma Treatment Landscape

EP: 7.Key Highlights For Patient Education Surrounding FGFR Inhibitors

Now Viewing

EP: 8.Common Adverse Events Associated With FGFRi Therapy

EP: 9.Patient Perspective Regarding FGFRi Adverse Event Profiles

EP: 10.Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

EP: 11.Monitoring and Managing Hyperphosphatemia

EP: 12.Navigating FGFRi Therapy Adverse Effects: Nail Toxicities

EP: 13.FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

EP: 14.Key Takeaways For Treating Patients Diagnosed With Cholangiocarcinoma

This page is funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this page is not medical advice and does not replace independent medical judgment.

This is a video synopsis/summary of a OncLive Insights involving Lipika Goyal, MD; Chaundra Bishop; R. Katie Kelley, MD; and Caroline Kuhlman, NP.

Goyal explained that as pan-FGFR inhibitors, pemigatinib and futibatinib frequently cause hyperphosphatemia due to on-target FGFR1 effects on renal phosphorus wasting and gastrointestinal absorption. Continuous futibatinib dosing leads to a higher incidence than intermittent pemigatinib’s 2 weeks on/1 week off schedule.

Diarrhea (20%-50%) also occurs owing to FGFR4 inhibition. Nail toxicities like brittleness, breakage, and perionychia arise in 20% to 60% of patients. Ophthalmic issues include blurry vision (3%-24%), prompting baseline and ongoing eye exams to monitor for retinal detachment and central serous retinopathy risks. Mouth sores (stomatitis) arise in 7% to 58% of patients, while dry mouth/eyes occur in 20% to 45%. Other potential toxicities include rash, hair loss (20%-50%), and hand-foot syndrome (5%-33%).

Kelly has not observed many serious adverse events definitively attributable to FGFR inhibitors. Rare potential hypersensitivity reactions manifesting as grade 3 rashes have occurred. Although theoretic with hyperphosphatemia, clinically significant calcium-phosphorus deposition has not been confirmed. Goyal added rapidly progressive cataracts, arising on/shortly after treatment, to the toxicity profile.

In summary, physicians should counsel patients on hyperphosphatemia, diarrhea, and ocular adverse effect likelihoods with pan-FGFR inhibitors. Most adverse events prove manageable, but impacts can be chronic. While not fully characterized, the role of FGFR signaling in ocular physiology warrants additional investigation regarding associated toxicities.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.